Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBP-418 Open-Label Extension in LGMD2I/R9
NCT07678775Phase 3Active, not recruiting
- Sponsor
- ML Bio Solutions
- Start
- Jun 2026
- Primary completion
- Oct 2030
- Countries
- 8
01
Overview
A Phase 3 trial of ribitol in limb-girdle muscular dystrophy type 2I (LGMD2I), sponsored by ML Bio Solutions. Started Jun 2026; status: active, not recruiting.
02
Drugs
ribitol
03
Conditions
limb-girdle muscular dystrophy type 2I (LGMD2I)
Beyond the preview
Go deeper on NCT07678775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07678775.